Biorestorative Therapies (NASDAQ:BRTX) Stock Rating Lowered by Maxim Group

Biorestorative Therapies (NASDAQ:BRTX) was downgraded by investment analysts at Maxim Group from a “buy” rating to a “hold” rating in a report released on Tuesday, Marketbeat.com reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, August 24th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Biorestorative Therapies Trading Down 1.3%

Shares of BRTX stock opened at $2.24 on Tuesday. The company has a market capitalization of $3.09 million, a price-to-earnings ratio of -0.10 and a beta of 0.94. The firm has a 50-day moving average price of $3.39 and a 200 day moving average price of $5.13. Biorestorative Therapies has a twelve month low of $2.01 and a twelve month high of $34.60.

Biorestorative Therapies Company Profile

BioRestorative Therapies, Inc is a biotechnology company focused on developing regenerative medicine products using cell-based therapies. The company’s research programs are aimed primarily at treating musculoskeletal disorders and conditions associated with metabolic health.

Its principal product candidate is BRTX-100, an autologous cell therapy being developed for painful degenerative disc disease. The treatment is designed to use a patient’s own bone marrow-derived cells, which are processed and expanded before being administered to the affected spinal disc.